Abstract
In most countries the prevalence of obesity now exceeds 15%, the figure used by the World Health Organization to define the critical threshold for intervention in nutritional epidemics. Here we describe Homo obesus (man the obese) as a recent phenotypic expression of Homo sapiens. Specifically, we classified Homo obesus as a species deficient of metabotrophic factors (metabotrophins), including endogenous proteins, which play essential role in the maintenance of glucose, lipid, energy and vascular homeostasis, and also improve metabolism-related processes such as inflammation and wound healing. Here we propose that pharmaceuticals, nutraceuticals and xenohormetics targeting transcriptional, secretory and/or signaling pathways of metabotrophins, particularly adiponectin, nerve growth factor, brain-derived neurotrophic factor, interleukin-10, and sirtuins, might be new tools for therapy of Homo obesus. Brief comment is also given to (i) exogenous metabotrophic agents represented by various classes of drugs, and (ii) adiponutrigenomics of lifspan.
Keywords: Metabotrophins, metabotrophin-targeted pharmacology
Current Pharmaceutical Design
Title: Homo obesus: A Metabotrophin-Deficient Species. Pharmacology and Nutrition Insight
Volume: 13 Issue: 21
Author(s): G.N. Chaldakov, M. Fiore, A.B. Tonchev, D. Dimitrov, R. Pancheva, G. Rancic and L. Aloe
Affiliation:
Keywords: Metabotrophins, metabotrophin-targeted pharmacology
Abstract: In most countries the prevalence of obesity now exceeds 15%, the figure used by the World Health Organization to define the critical threshold for intervention in nutritional epidemics. Here we describe Homo obesus (man the obese) as a recent phenotypic expression of Homo sapiens. Specifically, we classified Homo obesus as a species deficient of metabotrophic factors (metabotrophins), including endogenous proteins, which play essential role in the maintenance of glucose, lipid, energy and vascular homeostasis, and also improve metabolism-related processes such as inflammation and wound healing. Here we propose that pharmaceuticals, nutraceuticals and xenohormetics targeting transcriptional, secretory and/or signaling pathways of metabotrophins, particularly adiponectin, nerve growth factor, brain-derived neurotrophic factor, interleukin-10, and sirtuins, might be new tools for therapy of Homo obesus. Brief comment is also given to (i) exogenous metabotrophic agents represented by various classes of drugs, and (ii) adiponutrigenomics of lifspan.
Export Options
About this article
Cite this article as:
G.N. Chaldakov , M. Fiore , A.B. Tonchev , D. Dimitrov , R. Pancheva , G. Rancic and L. Aloe , Homo obesus: A Metabotrophin-Deficient Species. Pharmacology and Nutrition Insight, Current Pharmaceutical Design 2007; 13 (21) . https://dx.doi.org/10.2174/138161207781039616
DOI https://dx.doi.org/10.2174/138161207781039616 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery
Current Pharmaceutical Design Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Current Gene Therapy Scaffolds for Bone Regeneration: State of the Art
Current Pharmaceutical Design The Concept of a Green Drug, Curcumin and It ’ s Derivatives as a Model System
Mini-Reviews in Organic Chemistry Immunossupressant and Organ Transplantation: Immunophilins Targeting Agent and Alternative Therapies
Current Medicinal Chemistry Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics Recommendations for Severe Hypertriglyceridemia Treatment, are there New Strategies?
Current Vascular Pharmacology Isolated-Perfused Heart: The Preparation that has been used as a Research Tool for More than a Century
Drug Design Reviews - Online (Discontinued) Modulation of Staurosporine-Activated Volume-Sensitive Outwardly Rectifying Cl- Channel by PI3K/Akt in Cardiomyocytes
Current Pharmaceutical Design Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Electronegative LDL: An Active Player in Atherogenesis or a By- Product of Atherosclerosis?
Current Medicinal Chemistry Nitrogen Containing Privileged Structures and their Solid Phase Combinatorial Synthesis
Combinatorial Chemistry & High Throughput Screening Oxidative Stress, Antioxidants, and Endothelial Function
Current Medicinal Chemistry Biologically Responsive Nanosystems Targeting Cardiovascular Diseases
Current Drug Delivery Polypharmacological Properties and Therapeutic Potential of β-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise
Current Pharmaceutical Design Multi-Target Profile of Oleocanthal, An Extra-Virgin Olive Oil Component
Current Bioactive Compounds Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry N-Acetylcysteine and Other Preventive Measures for Contrast-Induced Nephropathy in the Intensive Care Unit
Current Medicinal Chemistry Heterocyclic N-Oxides - An Emerging Class of Therapeutic Agents
Current Medicinal Chemistry